The new bisphosphonate, Zometa® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate
Allan Lipton, E. Small, Fred Saad, D. Gleason, David Gordon, M. Smith, Lee Rosen, M. Ortu Kowalski, Dirk Reitsma, John Seaman
Dive into the research topics of 'The new bisphosphonate, Zometa® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate'. Together they form a unique fingerprint.